NCT06227546View on ClinicalTrials.gov

MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

April 15, 2024

Primary Completion Date

March 28, 2025

Study Completion Date

May 31, 2026

Conditions
Extensive-stage Small-cell Lung Cancer
Interventions
DRUG

MGC018

Intravenous (IV) Infusion, 2.7 mg/kg on Day 1 of each 28 day cycle

Trial Locations (1)

20007

Lombardi Comprehensive Cancer Center, Georgetown University, Washington D.C.

Sponsors

Collaborators (1)

MacroGenics
All Listed Sponsors
collaborator

MacroGenics

INDUSTRY

lead

Georgetown University

OTHER

NCT06227546 - MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer | Biotech Hunter | Biotech Hunter